June 10, 2022
Xue-Qiao Zhao, MD
Research Professor of Medicine/Cardiology
Director, Clinical Atherosclerosis Research Lab
University of Washington
Overview:
Learning Objectives
Upon completion of this program, attendees should be able to
- Describe the association between higher levels of Lp(a) and increased risk of ASCVD
- Review the current recommendations of using Lp(a) for risk stratification
- Introduce the new anti-sense therapy for lowering Lp(a) and the HORIZON trial